DK3298036T3 - Fremgangsmåder til forberedelse af modificeret von Willebrand faktor - Google Patents

Fremgangsmåder til forberedelse af modificeret von Willebrand faktor Download PDF

Info

Publication number
DK3298036T3
DK3298036T3 DK16725477.0T DK16725477T DK3298036T3 DK 3298036 T3 DK3298036 T3 DK 3298036T3 DK 16725477 T DK16725477 T DK 16725477T DK 3298036 T3 DK3298036 T3 DK 3298036T3
Authority
DK
Denmark
Prior art keywords
methods
von willebrand
willebrand factor
preparing modified
modified von
Prior art date
Application number
DK16725477.0T
Other languages
English (en)
Inventor
Stefan Schulte
Hans-Wilhelm Beltz
Sabine Pestel
Thomas Weimer
Matthias Pelzing
Original Assignee
CSL Behring Lengnau AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring Lengnau AG filed Critical CSL Behring Lengnau AG
Application granted granted Critical
Publication of DK3298036T3 publication Critical patent/DK3298036T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1741—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals alpha-Glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/473—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used alpha-Glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/96—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation using ion-exchange
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
DK16725477.0T 2015-05-22 2016-05-20 Fremgangsmåder til forberedelse af modificeret von Willebrand faktor DK3298036T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15168934 2015-05-22
PCT/EP2016/061440 WO2016188905A1 (en) 2015-05-22 2016-05-20 Methods for preparing modified von willebrand factor

Publications (1)

Publication Number Publication Date
DK3298036T3 true DK3298036T3 (da) 2022-06-07

Family

ID=53191564

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16725477.0T DK3298036T3 (da) 2015-05-22 2016-05-20 Fremgangsmåder til forberedelse af modificeret von Willebrand faktor

Country Status (17)

Country Link
US (3) US10772936B2 (da)
EP (2) EP4089109A3 (da)
JP (1) JP6651548B2 (da)
KR (1) KR20180012303A (da)
CN (1) CN107810194B (da)
AU (1) AU2016267539B2 (da)
BR (1) BR112017024714A2 (da)
CA (1) CA2986625A1 (da)
DK (1) DK3298036T3 (da)
ES (1) ES2912300T3 (da)
HK (1) HK1250724A1 (da)
IL (1) IL255711A (da)
MX (1) MX2017014872A (da)
RU (1) RU2017145002A (da)
SG (2) SG10201910900WA (da)
TW (1) TW201713686A (da)
WO (1) WO2016188905A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017358861B2 (en) 2016-11-11 2022-02-17 CSL Behring Lengnau AG Truncated von Willebrand Factor polypeptides for treating hemophilia
ES2908008T3 (es) 2016-11-11 2022-04-27 CSL Behring Lengnau AG Polipéptidos truncados del Factor de von Willebrand para su administración extravascular en el tratamiento o profilaxis de un trastorno de la coagulación sanguínea
EP3641800B1 (en) 2017-06-22 2023-10-04 CSL Behring Lengnau AG Modulation of fviii immunogenicity by truncated vwf
AU2020300820A1 (en) * 2019-07-04 2022-03-03 CSL Behring Lengnau AG A truncated von willebrand factor (vWF) for increasing the in vitro stability of coagulation factor VIII
TW202126284A (zh) * 2019-09-30 2021-07-16 美商百歐維拉提夫治療公司 慢病毒載體配製物

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
AU6029594A (en) 1993-01-15 1994-08-15 Enzon, Inc. Factor viii - polymeric conjugates
WO1996018412A1 (en) 1994-12-12 1996-06-20 Beth Israel Hospital Association Chimeric cytokines and uses thereof
AU6455896A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
PT1754718E (pt) 1996-04-24 2011-07-13 Univ Michigan Factor viii resistente à inactivação
US20040092442A1 (en) 1996-04-24 2004-05-13 University Of Michigan Inactivation resistant factor VIII
JP2001507215A (ja) * 1997-01-16 2001-06-05 サイテル コーポレイション 組換え糖タンパク質のインビトロでの実用的なシアリル化
CA2329768C (en) 1998-04-27 2008-06-10 Opperbas Holding B.V. Pharmaceutical composition comprising factor viii and neutral liposomes
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US7615622B2 (en) 2001-01-12 2009-11-10 University Of Maryland, Baltimore Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
WO2002103024A2 (en) 2001-06-14 2002-12-27 The Scripps Research Institute Stabilized proteins with engineered disulfide bonds
EP1572936A2 (en) 2002-03-05 2005-09-14 Eli Lilly And Company Heterologous g-csf fusion proteins
DK1497330T3 (da) 2002-04-29 2010-06-14 Sanquin Bloedvoorziening Antagonister af faktor-VIII-interaktion med lav-densitets- lipoproteinreceptor-relateret protein
PL377731A1 (pl) * 2002-12-23 2006-02-06 Bristol-Myers Squibb Company Sposoby hodowli komórek ssaczych do wytwarzania białka
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
EP1596887B1 (en) 2003-02-26 2022-03-23 Nektar Therapeutics Polymer-factor viii moiety conjugates
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
SI1624891T2 (sl) 2003-05-06 2013-09-30 Biogen Idec Hemophilia Inc. Strjevalni faktor-FC himerni proteini za zdravljenje hemofilije
SI1641823T1 (sl) 2003-06-12 2011-12-30 Lilly Co Eli Fuzijski proteini analogni glp-1
ES2387028T3 (es) 2003-12-31 2012-09-12 Merck Patent Gmbh Proteína de fusión de Fc-eritropoyetina con farmacocinética mejorada
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
RU2423380C2 (ru) 2004-11-12 2011-07-10 БАЙЕР ХЕЛСКЕА ЛЛСи Сайт-направленная модификация fviii
DK1835938T3 (da) 2004-12-27 2013-11-04 Baxter Int Polymer-von Willebrand-faktor-konjugater
KR20080007226A (ko) 2005-04-14 2008-01-17 체에스엘 베링 게엠베하 증가된 안정성을 가진 변형된 응고 인자 ⅷ 및 이의 유도체
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
AU2007245190B2 (en) 2006-03-31 2011-07-21 Takeda Pharmaceutical Company Limited Pegylated factor VIII
AU2007260185B2 (en) 2006-06-14 2013-01-31 Csl Behring Gmbh Proteolytically cleavable fusion protein comprising a blood coagulation factor
PL2041270T3 (pl) 2006-07-13 2014-04-30 Wyeth Llc Wytwarzanie glikoprotein
KR101542752B1 (ko) 2006-12-22 2015-08-10 체에스엘 베링 게엠베하 연장된 생체내 반감기를 갖는 변형된 응고 인자
SG10201503304RA (en) 2007-12-27 2015-06-29 Baxter Int Cell culture processes
WO2009156137A1 (en) 2008-06-24 2009-12-30 Csl Behring Gmbh Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
US8759293B2 (en) 2009-11-13 2014-06-24 Grifols Therapeutics Inc. von Willebrand factor (vWF)-containing preparations, and methods, kits, and uses related thereto
PT2563906T (pt) 2010-04-26 2018-02-16 Novartis Ag Processo para cultivo de células cho
AU2012340501A1 (en) 2011-12-19 2013-07-11 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
SI2804623T1 (sl) 2012-01-12 2020-02-28 Bioverativ Therapeutics Inc. Himerni polipeptidi faktorja VIII in njihove uporabe
DK2814502T3 (da) 2012-02-15 2017-12-18 Csl Behring Gmbh Von Willebrand Faktor varianter med forbedret Faktor VIII bindingsaffinitet
US20150080309A1 (en) 2012-04-24 2015-03-19 Nova Nordisk A/S Compounds Suitable for Treatment of Haemophilia
SE537059C2 (sv) * 2012-12-21 2014-12-23 Nätstations Alliansen Ab Elcentral
US20160207977A1 (en) * 2013-06-12 2016-07-21 Novo Nordisk A/S Compounds Suitable for Treatment of Haemophilia

Also Published As

Publication number Publication date
BR112017024714A2 (pt) 2018-09-11
EP3298036B1 (en) 2022-04-06
EP4089109A3 (en) 2023-03-01
US10772936B2 (en) 2020-09-15
AU2016267539A1 (en) 2017-11-16
EP4089109A2 (en) 2022-11-16
CA2986625A1 (en) 2016-12-01
CN107810194A (zh) 2018-03-16
US11564976B2 (en) 2023-01-31
US20200368327A1 (en) 2020-11-26
AU2016267539B2 (en) 2019-12-05
TW201713686A (en) 2017-04-16
SG11201708754XA (en) 2017-12-28
US20210121535A1 (en) 2021-04-29
WO2016188905A1 (en) 2016-12-01
MX2017014872A (es) 2018-07-06
ES2912300T3 (es) 2022-05-25
US20180153968A1 (en) 2018-06-07
SG10201910900WA (en) 2020-01-30
US10905747B2 (en) 2021-02-02
KR20180012303A (ko) 2018-02-05
IL255711A (en) 2018-04-30
JP2018515125A (ja) 2018-06-14
RU2017145002A (ru) 2019-06-24
CN107810194B (zh) 2021-10-08
JP6651548B2 (ja) 2020-02-19
HK1250724A1 (zh) 2019-01-11
EP3298036A1 (en) 2018-03-28

Similar Documents

Publication Publication Date Title
DK3294700T3 (da) Fremgangsmåde til fremstilling af limonen-4-ol
DK3556775T3 (da) Anti-lag-3 antistoffer til behandling af hæmatologiske maligniteter
DK3110988T3 (da) Metoder til behandling af lithiumholdige materialer
DK3186376T3 (da) Fremgangsmåder til forbedring af cas9-medieret manipulationseffektivitet
DK3180363T3 (da) Sirp-alpha-immunoglobulin fusionsproteiner
DK3122444T3 (da) Fremgangsmåde til fremstilling af membraner
DK3400002T3 (da) Muteret, trunkeret von willebrand faktor
DK3515990T3 (da) Fremgangsmåde til fremstilling af lignocellulosematerialer
DK3529233T3 (da) Fremgangsmåde til fremstilling af 3-alkylsulfanyl-2-chlor-n-(1-alkyl-1h-tetrazol-5-yl)-4-trifluoromethyl-benzamider
DK3183237T3 (da) Fremgangsmåde til fremstilling af 5-fluor-1h-pyrazoler startende ud fra hexafluorpropen
DK3164150T3 (da) Modificeret von willebrand-faktor
DK3191498T3 (da) Fremgangsmåde til fremstilling af 2'-o-fucosyllactose
DK3400238T3 (da) Muteret von willebrand faktor
HK1250724A1 (zh) 用於製備經修飾的血管性血友病因子的方法
DK3534709T3 (da) Substituerede sulfonylamider til bekæmpelse af skadedyr
DK3408015T3 (da) Fremgangsmåde til fremstilling af emulsioner
DK3274143T3 (da) Fremgangsmåde til fremstilling af lignocellulosematerialer
DK3148984T3 (da) Fremgangsmåde til fremstilling af 5-fluor-1h-pyrazoler startende ud fra hexafluorpropen
DK3297656T3 (da) Trunkeret von Willebrand Faktor polypeptider til behandling af hæmofili
DK3253743T3 (da) Syntetisk fremgangsmåde til fremstilling af 2-furansyre-derivater
DK3265564T3 (da) Fremgangsmåde til modulering af mecp2-ekspression
DK3137449T3 (da) Fremgangsmåder til fremstilling af substituerede cycloseriner
DK3138556T3 (da) Fremgangsmåde til fremstilling af liposomer
DK3431590T3 (da) Fremgangsmåde til fremstilling af aktiveret hepatocytvækstfaktor (hgf)
DK3265483T3 (da) Modificeret von Willebrand-faktor med forbedret halveringstid